Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2021 - 2025)

Kiniksa Pharmaceuticals International's Research & Development history spans 5 years, with the latest figure at $34.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 1.72% year-over-year to $34.6 million; the TTM value through Dec 2025 reached $91.5 million, down 18.0%, while the annual FY2025 figure was $96.9 million, 13.23% down from the prior year.
  • Research & Development reached $34.6 million in Q4 2025 per KNSA's latest filing, up from $24.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $35.2 million in Q4 2024 to a low of $13.8 million in Q2 2022.
  • Average Research & Development over 5 years is $22.2 million, with a median of $22.3 million recorded in 2022.
  • Peak YoY movement for Research & Development: plummeted 47.54% in 2022, then surged 75.62% in 2024.
  • A 5-year view of Research & Development shows it stood at $27.4 million in 2021, then tumbled by 47.54% to $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then skyrocketed by 75.62% to $35.2 million in 2024, then decreased by 1.72% to $34.6 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Research & Development are $34.6 million (Q4 2025), $24.2 million (Q3 2025), and $18.8 million (Q2 2025).